Contract facts
FederalINCREMENTAL FUNDING FOR RESEARCH AND DEVELOPMENT SERVICES is a federal award for W6qk Acc-Apg held by Raytheon Company. Estimated value $63.9M ($19.7M obligated). Current period of performance ends Sep 30, 2027. Place of performance: MCKINNEY, TX.
INCREMENTAL FUNDING FOR RESEARCH AND DEVELOPMENT SERVICES
Recompete timing
PublicCurrent PoP ends Sep 30, 2027 (406 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Incumbent footprint
Public recordRaytheon Company — $2.6B obligated across 311 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W56KGY20F0010?
W56KGY20F0010 (Incremental funding for research and) is a W6qk Acc-Apg award with an estimated value of $63.9M, currently held by Raytheon Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W56KGY-20-F-0010?
W56KGY-20-F-0010 is the dashed form of PIID W56KGY20F0010 (Incremental funding for research and), held by Raytheon Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W56KGY20F0010?
W6qk Acc-Apg awarded W56KGY20F0010 to Raytheon Company.
Who is the incumbent on W56KGY20F0010?
Raytheon Company is the incumbent with $2.6B across 311 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2027.
When does Raytheon Company’s W56KGY20F0010 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.